Literature DB >> 14699016

Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis.

Jan H von der Thüsen1, Madelon L Fekkes, Robert Passier, A J van Zonneveld, V Mainfroid, Theo J C van Berkel, Erik A L Biessen.   

Abstract

OBJECTIVE: Restenosis remains a major late complication of percutaneous transluminal coronary angioplasty (PTCA), for which the development of prevention strategies has thus far been hampered by the lack of a representative and practical animal model. We have, therefore, developed a murine model of PTCA-induced restenosis. METHODS AND
RESULTS: Rigid probe angioplasty of pre-existing atherosclerotic lesions in the carotid arteries of ApoE-deficient mice was found to result in an increase in lesion size (0.14+/-0.04x10(5) microm2 to 0.42+/-0.09x10(5) microm2, P=0.007) with a smooth muscle cell-rich, fibrotic lesion morphology. In an additional experiment, lesions were incubated immediately after angioplasty with adenovirus bearing an endothelial nitric oxide synthase (eNOS) transgene (Ad.APT.eNOS), or an "empty" control virus (Ad.APT.empty) at a titer of 1.5x10(9) pfu/mL. Ad.APT.eNOS treatment was seen to lead to a 73.1% reduction in plaque size (0.27+/-0.04x10(5) microm2 versus 1.02+/-0.39x10(5) microm2, P=0.07), which translated to a significantly lowered average degree of stenosis (33.6+/-4.1% versus 74.6+/-14.0%, P=0.02). Ad.APT.eNOS also decreased lesional collagen content from 29.1% to 4.8% (P<0.001).
CONCLUSIONS: We believe that we have established a representative murine model of postangioplasty restenosis, which may serve to elucidate the mechanisms underlying restenosis and to evaluate potential antirestenotic therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14699016     DOI: 10.1161/01.ATV.0000114235.51044.92

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Mechanisms related to NO-induced motility in differentiated rat aortic smooth muscle cells.

Authors:  Qinghua Pu; Daming Zhuang; Shalini Thakran; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-29       Impact factor: 4.733

2.  Overexpression of endothelial nitric oxide synthase improves endothelium-dependent vasodilation in arteries infused with helper-dependent adenovirus.

Authors:  Bo Jiang; Liang Du; Rowan Flynn; Nagadhara Dronadula; Jingwan Zhang; Francis Kim; David Dichek
Journal:  Hum Gene Ther       Date:  2012-09-24       Impact factor: 5.695

3.  Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration.

Authors:  Hiroyuki Suzuki; Keita Kimura; Heigoro Shirai; Kunie Eguchi; Sadaharu Higuchi; Akinari Hinoki; Kazuhiro Ishimaru; Eugen Brailoiu; Danny N Dhanasekaran; Laura N Stemmle; Timothy A Fields; Gerald D Frank; Michael V Autieri; Satoru Eguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-12-18       Impact factor: 8.311

4.  Cyclic guanosine monophosphate-dependent protein kinase I promotes adhesion of primary vascular smooth muscle cells.

Authors:  Pascal Weinmeister; Robert Lukowski; Stefan Linder; Claudia Traidl-Hoffmann; Ludger Hengst; Franz Hofmann; Robert Feil
Journal:  Mol Biol Cell       Date:  2008-08-06       Impact factor: 4.138

5.  Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis.

Authors:  Robert Lukowski; Pascal Weinmeister; Dominik Bernhard; Susanne Feil; Michael Gotthardt; Joachim Herz; Steffen Massberg; Alma Zernecke; Christian Weber; Franz Hofmann; Robert Feil
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-17       Impact factor: 8.311

6.  Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier.

Authors:  Patrick H Kee; Melanie R Moody; Shao-Ling Huang; Hyunggun Kim; Xing Yin; Tao Peng; Susan T Laing; Melvin E Klegerman; Mohammad H Rahbar; Deborah Vela; Curtis Genstler; Kevin J Haworth; Christy K Holland; David D McPherson
Journal:  JACC Basic Transl Sci       Date:  2019-11-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.